The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 29, 2018

Filed:

Feb. 18, 2014
Applicants:

Hadasit Medical Research Services and Development Ltd., Jerusalem, IL;

The Brigham and Women's Hospital, Inc., Boston, MA (US);

Inventors:

Yaron Ilan, Jerusalem, IL;

Howard L. Weiner, Brookline, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 31/7032 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); A61K 31/7028 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 31/7028 (2013.01); A61K 31/7032 (2013.01); A61K 45/06 (2013.01); C07K 16/2809 (2013.01);
Abstract

The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, β-glycosphin-golipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-CD3 antibody. The invention further provides methods kits and uses of the combined compositions of the invention for immune-modulation and thereby for the treatment of immune-related disorders. In a preferred embodiment, anti-CD3 antibody (OKT3) is orally administered in combination with β-glucosylceramide (also known as glycocerebroside) in an animal model of type 2 diabetes.


Find Patent Forward Citations

Loading…